Quality of life and functioning in first‐episode psychosis Chinese patients with different antipsychotic medications

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Early Intervention in Psychiatry

• Publication date

  2016-12-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1111/eip.12246PMID 25967146
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Scale for the Assessment of Positive Symptoms

  2018cited by this paper
• Early intervention and evaluation for adult‐onset psychosis: the JCEP study rationale and design

  2014influential reference
• Scale for the Assessment of Negative Symptoms

  2014cited by this paper
• Humanistic burden in schizophrenia: a literature review.

  2014cited by this paper
• Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis.

  2013cited by this paper
• Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.

  2013cited by this paper
• Pharmacogenetics of antipsychotics: recent progress and methodological issues

  2013cited by this paper
• Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

  2012cited by this paper
• Progress in Defining Optimal Treatment Outcome in Schizophrenia

  2010cited by this paper
• Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention.

  2010cited by this paper
• Quality of life and mental health in Chinese culture

  2010cited by this paper
• Amisulpride versus other atypical antipsychotics for schizophrenia.

  2010cited by this paper
• A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia.

  2009cited by this paper
• Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.

  2009cited by this paper
• Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation

  2008cited by this paper
• Early intervention in psychosis: concepts, evidence and future directions

  2008cited by this paper
• Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.

  2007cited by this paper
• Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

  2006cited by this paper
• Impact of Atypical Antipsychotics on Quality of Life in Patients with Schizophrenia

  2004cited by this paper
• The Barnes Akathisia Rating Scale–Revisited

  2003cited by this paper
• Amisulpride vs Risperidone in Chronic Schizophrenia: Results of a 6-Month, Double-Blind Study

  2003cited by this paper
• Amisulpride vs. Risperidone in Chronic Schizophrenia: Results of a 6-month Double-blind Study

  2002cited by this paper
• Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.

  2001cited by this paper
• Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group.

  1999cited by this paper
• Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.

  1997cited by this paper
• A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity.

  1996cited by this paper
• Assessing levels of adaptive functioning: The Role Functioning Scale

  1993cited by this paper
• Revising axis V for DSM-IV: a review of measures of social functioning.

  1992cited by this paper
• The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients

  1987cited by this paper
• Measurement of premorbid adjustment in chronic schizophrenia.

  1982cited by this paper
• Diagnostic and Statistical Manual of Mental Disorder

  1980cited by this paper
• Drug, Healthcare and Patient Safety Dovepress Safety and Tolerability of Antipsychotics: Focus on Amisulpride

  year unknowncited by this paper

• Three-year outcome comparison between extended early intervention and standard psychiatric care for adults with first-episode psychosis in Hong Kong

  2025cites this paper
• Impact of financial deprivation in first-episode psychosis: a prospective 4-year follow-up study

  2025cites this paper
• A Systematic Review on the Effectiveness of Antipsychotic Drugs on the Quality of Life of Patients with Schizophrenia

  2023cites this paper
• Comparison of antipsychotic naïve first‐episode psychosis patients and healthy controls in Uganda

  2021cites this paper
• Incidence and risk factors of acute akathisia in 493 individuals with first episode non-affective psychosis: a 6-week randomised study of antipsychotic treatment

  2017cites this paper
• Clinical and treatment-related determinants of subjective quality of life in patients with first-episode psychosis.

  2017cites this paper
• Chapter 5 - Antipsychotic Drugs

  2016cites this paper